# EDGAR Filing Document

**Accession Number:** 0001553846
**File Stem:** 0001178913-26-000751
**Filing Date:** 2026-3
**Character Count:** 5277
**Document Hash:** f4131954941b04caa1db9650dac6ec91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000751.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001178913-26-000751

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260305

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RedHill Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001553846
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35773
- **FILM NUMBER:** 26724393

**BUSINESS ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739
- **BUSINESS PHONE:** 972-3-541-3131

**MAIL ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739

------

**UNITED STATES**

SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
FORM 6-K

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934
For the month of March 2026<br> Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant's name into English)

#### 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐ <br>

At the Extraordinary General Meeting of Shareholders of RedHill Biopharma Ltd. (the "<u>Company</u>") held on March 5, 2026, all of the resolutions proposed to the shareholders were duly approved. Below are the proposals adopted:

<br> 1. To approve the grant of restricted share units ("<u>RSUs</u>"), each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) to the non-executive directors of the Company;

<br> 2. To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company's Chief Executive Officer and Chairman of the Board of Directors;

<br> 3. To approve the grant of RSUs to Mr. Rick D. Scruggs, the Company's Chief Commercial Officer, and Director; and

<br> 4. To approve an increase in the Company's authorized share capital.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. [333-188286](https://www.sec.gov/Archives/edgar/data/1553846/000114420413025906/v343603_s8.htm)), on October 29, 2015 (Registration No. [333-207654](https://www.sec.gov/Archives/edgar/data/1553846/000117184315005802/gffs8_102915.htm)), on July 25, 2017 (Registration No. [333-219441](https://www.sec.gov/Archives/edgar/data/1553846/000117184317004282/fs8_072517.htm)), on May 23, 2018 (Registration No. [333-225122](https://www.sec.gov/Archives/edgar/data/1553846/000117184318004154/fs8_052218.htm)), on July 24, 2019 (File No. [333-232776](https://www.sec.gov/Archives/edgar/data/1553846/000117184319004739/s8_072419.htm)), on March 25, 2021 (File No. [333-254692](https://www.sec.gov/Archives/edgar/data/1553846/000117891321001175/zk2125809.htm)), on May 3, 2021 (File No. [333-255710](https://www.sec.gov/Archives/edgar/data/1553846/000117891321001554/zk2125949.htm)), on January 11, 2022 (File No. [333-262099](https://www.sec.gov/Archives/edgar/data/1553846/000117891322000075/zk2227037.htm)), on June 27, 2022 (File No. [333-265845](https://www.sec.gov/Archives/edgar/data/1553846/000117891322002482/zk2228053.htm)), on June 29, 2023 (File No. [333-273001](https://www.sec.gov/Archives/edgar/data/1553846/000117891323002325/zk2329924.htm)), on June 20, 2024 (File No. [333-280327](https://www.sec.gov/Archives/edgar/data/1553846/000117891324002009/zk2431594.htm)), on March 25, 2025 (File No. [333-286082](https://www.sec.gov/Archives/edgar/data/1553846/000117891325001017/zk2532919.htm)) and on January 22, 2026 (File No. [333-292879](https://www.sec.gov/Archives/edgar/data/1553846/000117891326000206/zk2634240.htm)), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. [333-254848](https://www.sec.gov/Archives/edgar/data/1553846/000117891321001221/zk2125824.htm)), on August 4, 2023 (File No. [333-273709](https://www.sec.gov/Archives/edgar/data/1553846/000117891323002694/zk2330099.htm)), on October 13, 2023 (File No. [333-274957](https://www.sec.gov/Archives/edgar/data/1553846/000117891323003368/zk2330395.htm)), as amended, and on August 9, 2024 (File No. [333-281417](https://www.sec.gov/Archives/edgar/data/1553846/000117891324002517/zk2431808.htm)). <br>

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | REDHILL BIOPHARMA LTD. | REDHILL BIOPHARMA LTD. |
|  | (the "Registrant") | (the "Registrant") |
| Date: March 5, 2026 | By: | /s/ Dror Ben-Asher |
|  | Name: | Dror Ben-Asher |
|  | Title: | Chief Executive Officer |

---

------